Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 16, 4:00 PM ET · Delayed 15 min
VNDA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $243.66M
- Forward P/E
- 20.15
- EPS (TTM)
- -$4.63
- Dividend yield
- None
- 52-week range
- 4.00 – 9.94
- Day range
- 4.00 – 4.27
- Volume / Avg
- 1.05M / 968.38K
- Beta
- —
- Shares outstanding
- 60.46M
- Next earnings
- Nov 4, 2026
52-week range
VNDA stock today
Shares of Vanda Pharmaceuticals (VNDA) finished lower on Oct 16 at $4.03, a drop of 4.95% or $0.21 per share, versus the S&P 500's 1.09% decline. Shares are 59.5% below their 52-week high of $9.94, set on Mar 10, 2026 and 0.9% above the 52-week low of $4.00, near the bottom of the past year's range. VNDA is down 54.3% year to date, underperforming the S&P 500 (+11.9%). Over the past 12 months, the stock has lost 23.5%.
Vanda Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.63), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 4; analysts expect EPS of -$0.72.
Summary generated from market data by MetaCap's automated system. Methodology
About Vanda Pharmaceuticals
Company profileVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Mihael H. Polymeropoulos M.D.
- Headquarters
- Washington, DC
- Employees
- 533
- IPO year
- 2006
- Website
- vandapharma.com
Financial highlights
Full financialsIn fiscal 2025, Vanda Pharmaceuticals generated $216.1 million in revenue, up 8.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Vanda Pharmaceuticals reported a net loss of $220.5 million, compared with a loss of $18.9 million a year earlier. Gross margin was 94.0% (down from 94.3%) and operating margin -70.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $216.10M | $198.77M | $192.64M | $254.38M | $268.68M |
| Growth | +8.72% | +3.18% | -24.27% | -5.32% | +8.27% |
| Net income | $-220.47M | $-18.90M | $2.51M | $6.28M | $33.15M |
| EPS (diluted) | $-3.74 | $-0.33 | $0.04 | $0.11 | $0.58 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$11.75+191.56%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.72
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-1.04 vs —
VNDA news
All VNDA newsVanda Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BCYCBicycle Therapeutics plc ADR | 3.46 | -3.89% | $242.18M | vs VNDA |
| LFCRLifecore Biomedical Inc. | 6.38 | -0.93% | $241.84M | vs VNDA |
| CATXPerspective Therapeutics Inc. | 2.17 | -7.26% | $247.71M | vs VNDA |
| RCKTRocket Pharmaceuticals Inc. | 2.18 | -7.63% | $239.31M | vs VNDA |
| AMRNAmarin Corporation plc | 11.32 | -2.16% | $239.11M | vs VNDA |
| ACIUAC Immune SA | 2.39 | -2.45% | $237.63M | vs VNDA |
| VCREVicore Pharma Holding AB ADR | 8.98 | -1.21% | $252.92M | vs VNDA |
| ABEOAbeona Therapeutics Inc. | 4.43 | -4.73% | $253.33M | vs VNDA |
Indexes, lists and sector
Vanda Pharmaceuticals stock FAQ
What is Vanda Pharmaceuticals's stock price today?
VNDA last traded at $4.03 as of Oct 16, 4:00 PM EDT, down 4.95% on the day. Prices are delayed at least 15 minutes.
When is Vanda Pharmaceuticals's next earnings date?
Vanda Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.72.
Who is Vanda Pharmaceuticals's CEO?
Dr. Mihael H. Polymeropoulos M.D. is the chief executive officer of Vanda Pharmaceuticals Inc., which has about 533 employees.
What is the VNDA 52-week high?
The 52-week high for VNDA is $9.94 and the 52-week low is $4.00. The stock is currently 59.5% below its high.